The TATTON trial reported an objective response rate of 33% with the combination of osimertinib and savolitinib (a MET inhibitor) in 69 patients with EGFR-mutated, MET-amplified NSCLC previously treated with a third-generation EGFR TKI. The gene discussed is MET; the disease is non-small cell lung carcinoma.